In recent years, new methods based on mutations and other molecular markers have been partially applied in differential diagnosis of thyroid tumors (e.g., BRAF, TP53, CTNNB1, and other genes), and these molecular markers have significantly improved the diagnostic accuracy of cytology and have had a profound impact on the classification and management of patients with thyroid tumors. This evidence concerns the gene TP53 and thyroid tumor.